Kornimate/medical-research-clean huggingface dataset:
children's dental anxiety in relation to parental dental anxiety, child's age and gender and caries experience

Conditions: Child Dental Anxiety

Summary: determine the relation of of children's dental anxiety to parental dental anxiety, child's age and gender and caries experience will be obtained through written questionnaires (acdas) and (cdas) to the child and parents of children aged 6-8 years old in the clinic.

1. soft copies of the abeer children dental anxiety scale (acdas) questionnaire and corah dental anxiety scale (cdas) questionnaire. 2. the child's age and gender will be recorded first. 3. level of anxiety will be recorded by using heart rate using fingertip pulse oximeter. 4. dental caries experiences will record by using dental caries indices (dmf and def) 5. child dental anxiety will be evaluated from (acdas) questionnaire: the first part is child self-report part, the operator will be answered by ticking the box that corresponds to child dental anxiety, 1 (happy), 2 (ok), 3 (scared). the second part about the cognitive part with five questions: three of them answered with (yes, no) and the other two questions answered with score, 1 (happy), 2 (ok), 3 (scared) 6. parents dental anxiety will be evaluated from (cdas) questionnaire. the parents will answer by ticking the answer. the final scores, \&gt;9 (mild anxiety), 9-12 (moderate anxiety), 13-14 (high anxiety), 15-20 (sever anxiety). 7. results will be analyzed by the statistician. 8. data handling will be supervised by the supervisors.

Eligibility criteria:
inclusion criteria: 1. children range in age from 6-8 years old. 2. first dental visit. 3. accompanied by their parents. 4. both male and female included. exclusion criteria: 1. children with physical or mental disabilities. 2. children who refuse to participate.

Keywords: parental dental anxiety child dental anxiety
effectiveness of functional pillow on neck pain, disability, quality of sleep and life

Conditions: Neck Pain; Posterior Cervical Pain; Sleep Disorders

Summary: the purpose of this study is to investigate the effects of functional cervical pillow on inpatients with neck discomfort.

50 inpatients with neck discomfort(nrs\>4) will be randomly allocated to 2 groups. the experimental group was treated with functional cervical pillow and the control group was treated with general pillow. all applications of pillow were limited to 3-4 weeks. primary outcomes were measured using the vas scale. post-treatment follow-up will be performed to measure primary outcomes at baseline, 3 day, per weeks until the duration of admission. satisfaction levels of the patient's current status, neck disability index(ndi) psqi, eq-5d will also be collected. the applicants will also get thru the diagnosis of range of motion by x-ray(flexion, neutral, extension of their neck position)

Eligibility criteria:
inclusion criteria: * patients admitted to a korean medicine hospital * age between 18 and 69 * nrs score of \>4 on the day of the intervention * voluntary participation with written consent given to study consent form, including cervical x-ray exclusion criteria: * diagnosis of serious disease(s) which are possible causes of neck pain such as malignancy, vertebral fracture, spinal infection, inflammatory spondylitis, cauda-equina compression, etc. * prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, alzheimer's disease, epilepsy, etc. * progressive neurologic deficit(s) or concurrent severe neurological symptoms * previously using any kind of functional pillow

Keywords: neck pain functional pillow sleep cervical lordosis
demineralized whole-tooth vs demineralized particulate dentin grafts in alveolar ridge preservation

Conditions: Alveolar Bone Loss

Summary: the aim of this trial is to compare whole-tooth vs particulate dentin for their effects in alveolar ridge preservation.

extraction of the teeth is still one of the most commonly undertaken procedures in dental practices due to various reasons that render the teeth non-restorable. following extraction, replacing the lost teeth with a prosthetic alternative that provides for both optimal esthetics and function can be challenging due to the inevitable events of socket healing that results in the reduction in alveolar bone height and width. to overcome these limitations and provide for adequate ridge volume, different bone preservation or augmentation techniques can be utilized with different clinical applications. alveolar ridge preservation is a procedure that attempts to reduce bone dimensional changes that naturally take place following tooth extraction. to overcome this problem, various approaches using various grafting materials and/or covering membranes have been proposed with varied success. the extracted tooth is no longer considered as clinical waste, it has been explored as an appropriate source for autogenous graft substitute. this idea emerged due to the shared embryonic origin of bone and teeth as well as the similarities in chemical structure as dentin is composed of 30-35% organic part and 65-70% inorganic part in comparison to alveolar bone, with inorganic and organic parts of 35% and 65% respectively. both whole-tooth and particulate forms has been utilized for alveolar ridge preservation or augmentation but the superiority of one form over the other is not yet clear.

Eligibility criteria:
inclusion criteria: * non-restorable tooth indicated for extraction * single-rooted teeth * patients at least 18 years or older * motivated patients, agree to sign informed consent and complete the follow-up period exclusion criteria: * pregnant females * active infection at extraction site * smokers * systemic conditions affecting healing (e.g. diabetes, medications as bisphosphonates...)
is the nerve growth factor (ngf) a useful biomarker in neurogenic bladder dysfunction after spinal cord injury?

Conditions: Spinal Cord Injury; Neurogenic Detrusor Overactivity; Neurogenic Lower Urinary Tract Dysfunction

Summary: spinal cord injury (sci) almost always affects bladder function as well. as a result of this bladder dysfunction, individuals with sci have to undergo regular invasive examination of their bladder function (urodynamic examination). the nerve growth factor (ngf) is released from smooth muscle cells of the bladder, and there are reports, that the concentration of ngf is elevated in the urine of patients with bladder dysfunction. the ngf concentration can also be measured in the blood. the concentration of ngf in the blood and urine of sci individuals has not yet been investigated. these concentrations may correlate with the severity of bladder dysfunction, and may thus be used to replace or at least reduce the number of the more invasive urodynamic examinations. the hypothesis that urine and blood ngf concentrations in individuals with sci are higher compared to individuals with healthy bladder function will be tested.


Eligibility criteria:
control group inclusion criteria: * physiologic bladder function exclusion criteria: * no signed consent form * age \ 80 years * urinary tract infection * bladder surgery * radiation therapy of the pelvic area * pregnancy * bleeding disorder study group inclusion criteria: * neurogenic detrusor overactivity * presentation for urodynamic examination exclusion criteria: * no signed consent form * age \ 80 years * urinary tract infection * bladder augmentation * bladder evacuation by permanent catheterization * radiation therapy of the pelvic area * pregnancy * bleeding disorder

Keywords: spinal cord injury neurogenic lower urinary tract dysfunction nerve growth factor neurogenic detrusor overactivity urodynamics
real-world assessment of therapeutic strategies and survival outcomes following first-line tislelizumab therapy in advanced non-small cell lung cancer

Conditions: Non-Small-Cell Lung Cancer; Non-Small-Cell Lung Cancer Stage IV

Summary: this study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line tislelizumab treatment in advanced nsclc. based on the inclusion and exclusion criteria, patients with advanced nsclc who received first-line tislelizumab treatment and progressed will be retrospectively screened and collected from january 1, 2020, to the study initiation date, and followed up for observation.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed unresectable locally advanced or metastatic nsclc based on the 8th edition of the ajcc staging system. * previously received first-line treatment with tislelizumab for advanced nsclc. * medical records of disease progression after first-line treatment. exclusion criteria: * patients with incomplete key baseline and treatment information，including clinical stage, pathological type, treatment regimen, tumor assessment record after treatment ect. * patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.

Keywords: advanced non-small-cell lung cancer real-world study tislelizumab progression
thorax computed tomography severity score and outcome in covid-19 patients

Conditions: COVID-19

Summary: the most common thorax computed tomography (ct) findings are multifocal ground-glass opacities and peripheral consolidation in patients with covid-19. septal thickening, bronchiectasis, pleural thickening, and subpleural involvement may also be observed. although these findings are not specific to covid-19, the severity of pulmonary involvement is expected to be correlated with thorax ct findings.

thorax computed tomography severity score defined by yang et al. can be used to evaluate the severity of pulmonary involvement in covid-19 patients. we aimed to investigate whether the initial thorax computed tomography severity score can predict mechanical ventilation requirement and mortality in covid-19 patients.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * covid-19 confirmed by positive rt-pcr and/or antibody testing * ct scan at intensive care unit admission exclusion criteria: * loss of ct data * chronic lung disease findings by ct that may lead to misinterpretation * rt-pcr results unavailable or negative * terminal cancer
evaluating the neurophysiologic and clinical effects of single dose drug challenge

Conditions: Fragile X Syndrome

Summary: the aim of this study is to utilize neurophysiologic assessments, behavioral measures and clinical measures to assess how much deficits associated with fragile x syndrome from pre-dose to post-dose using pharmacology.


Eligibility criteria:
inclusion criteria: * subjects ages 18-45, with fxs who completed the study entitled "mechanisms and brain circuits underlying fragile x syndrome" (irb # 2015-8425) or appropriate baseline measures through biorepository (2013-7327). * fxs is defined as full fmr1 mutations (\>200 cgg repeats) confirmed by genetic testing. * general good health as determined by physical exam, medical history and laboratory work up. * stanford binet iq \<85 * stable dosing of psychotropic drugs for at least 4 weeks. exclusion criteria: * subjects with a history of intolerance to baclofen, roflumilast, or memantine will be excluded. * subjects will also be excluded if they have taken any investigational drug within 3 months, have a history of substance abuse or dependence within 6 months, or significant psychiatric or cns neurological disease unrelated to fxs. * uncontrolled seizures or history of epilepsy with a seizure in the past 6 months * auditory or visual impairments that cannot be corrected based on visual and auditory screener benchmarks. * moderate to severe renal or hepatic impairment and determined by a study physician incorporating data from exam, medical history and laboratory value evaluation among other data points. * use of barbiturates, benzodiazepines, antiepileptics, or other gabaergic or glutamatergic modulators * current use of: amifampridine, butalbital, codeine, doxylamine, ethanol, hydrocodone, isocarboxazid, kava, metoclopramide, midazolam, oxybate, phenelzine, promethazine, thalidomide, tranylcypromine, trimethobenzamide, erythromycin, ketoconazole, fluvoxamine, enoxacin, and cimetidine. * those taking other psychiatric medications must be on stable doses for 4 weeks before the baseline visit. * pregnancy or breast-feeding. for female subjects of child bearing potential, a urine pregnancy test will be performed. * potential subjects with a creatinine clearance \< 50 ml/min will be excluded. * identified medical issues, inability to tolerate study procedures or study drug per the discretion of the principal investigator.
the impact of the type and route of nutritional support on infectious complications after upper gastrointestinal surgery

Conditions: Gastrointestinal Surgery

Summary: the study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper gi surgery

all patients qualified between june 2002 and december 2007 to total and distal subtotal gastrectomy or pancreaticoduodenectomy were screened for eligibility to participate in the study. malnutrition was defined by the nutritional risk index (nri), calculated according to the formula used in the veterans administration cooperative group trial.{, 1991 #70} additional eligibility criteria included: age between 18 and 80 years, karnofsky performance status score of 80 or more, and adequate organ function measured by routine blood tests. patients without features of malnutrition, as well as those with disseminated tumors, serious comorbidities (american society of anesthesiologists risk class of 4 or 5), and renal or liver failure were excluded. the study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications in a population of malnourished patients following elective upper gi surgery. therefore, patients were randomly assigned in a 2×2 factorial design to four groups receiving immunostimulating versus normal diets, and enteral versus intravenous nutritional support. the secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and the length of hospital stay.

Eligibility criteria:
inclusion criteria: * age between 18 and 80 years, * karnofsky performance status score of 80 or more, * adequate organ function measured by routine blood tests exclusion criteria: * patients \ 80 * karnofsky performance \< 50

Keywords: immunonutrition surgical patients postoperative period
clinical trial assessing the immunologic response to a influenza vaccine delivered using an jet injection device or a needle syringe

Conditions: Influenza Prophylaxis

Summary: the primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response. a secondary objective was to compare the safety of the two delivery methods.

needle-free jet injection devices create a fine stream of pressurized liquid that is able to deliver vaccines and other pharmaceutical products beneath the skin. design aspects such as quality, pressure, orifice size, angle of injection relative to skin and injection stream coherence control the depth to which the product is delivered. this technology provides a safer delivery option for patients and healthcare staff by removing the need for needles for the administration of vaccines. in addition to improved safety, additional benefits of using jet injectors include more consistent and reliable dose volume delivery, reduced vaccine waste, diminished need to transport large quantities of sharps, reduced risk of needle sticks, syringe reuse, and costs associated with sharps waste. jet injectors offer a needle-free procedure to those individuals who are adverse to needles. this study compared the efficacy of a disposable syringe jet injection device (stratis) with traditional needle and syringe (ns) administration for the delivery of a trivalent inactivated influenza vaccine. efficacy was evaluated by comparing measures of hemagglutination inhibition (hi); specifically gmts, seroconversion and seroprotection. safety of the two administration devices was evaluated by comparison of incidence of solicited local and systemic adverse events.

Eligibility criteria:
inclusion criteria: * female and male subjects ages 18 to 59 years * healthy volunteers * able to provide informed consent and understand study procedures per ich/gcp guidelines * plans to remain in study area for length of the trial; able to adhere to study visit and follow-up schedule * able to complete study diary exclusion criteria: * unwilling or unable to undergo the two blood draws per protocol * have received influenza vaccination in the last twelve months * have received any vaccination in the last month * currently taking antibiotics, steroids, phenytoin, chemotherapy, or other immunosuppressive drugs * received recent blood, blood products, or parenteral preparations of immunoglobulin (within 3 months) * suffers from allergic reactions to egg, gelatin, or neomycin or has a history of anaphylactic shock, asthma, urticaria, or other allergic reactions to vaccinations. * had any serious adverse event associated with a prior vaccination * has immunodeficiency or autoimmune disease (including hiv) * history of chronic alcohol abuse * participating in another study concurrently * pregnant or breastfeeding during the study

Keywords: jet injector stratis® pharmajet jet injection
observational study of the argus® ii retinal prosthesis system

Conditions: Retinitis Pigmentosa

Summary: the argus ii retinal implant is a revolutionary new device, which offers vision to patients who are blind from retinal degeneration - retinitis pigmentosa. these patients have no alternatives. patients typically can achieve ambulatory vision.

this study is an investigator-sponsored, observational, controlled, prospective, single-center study. the purpose of this current study is how it affects people's visual function and activities of daily living and to collect additional data on argus ii users in order to monitor the system's safety. in addition, data about the long-term reliability of the system will be gathered. the argus ii retinal implant will be surgical implanted into patients who are blind but the surgical procedure is not a part of this observational study. our hypothesis is that the visual results in our hands will be comparable to those reported in the fda study. we will use the results of this study to plan future enhancements to the service and to explore the use of the device for other blinding conditions.

Eligibility criteria:
inclusion criteria: •adults, age 25 years or older with severe to profound outer retinal degeneration. but some residual light perception. if no residual light perception remains, the retina must be able to respond to electrical stimulation and previous history of useful form vision. exclusion criteria: * ocular diseases or conditions that could prevent the argus ii system from working (e.g. optic nerve disease, central retinal artery or vein occlusion, history of retinal detachment, trauma, severe strabismus). * ocular structures or conditions that could prevent the successful implantation of the argus ii implant or adequate healing from surgery (e.g. extremely thin conjunctiva, axial length \ 26 mm, corneal ulcers, choroidal neovascularisation in the area of the intended tack location, etc.). * ocular diseases or conditions (other than cataracts) that prevent adequate visualisation of the inner structures of the eye (e.g. corneal opacity, etc.). * inability to tolerate general anaesthesia or the recommended antibiotic and steroid regimen associated with the implantation surgery. * predisposition to eye rubbing.
epinephrine nasal drops for epistaxis during nasal intubation

Conditions: Oral Surgery

Summary: epistaxis is the most common complication of nasotracheal intubation. incidence of epistaxis during nasotracheal intubation ranges from 22% to 80%. epistaxis during nasotracheal intubation can lead to several complications such as nasal discomfort, airway obstruction, and blood aspiration. the most commonly used and available topical vasoconstrictor in drop form is oxymetazoline. however, oxymetazoline may not always be available in some hospitals, so epinephrine can be used as an alternative nasal decongestant to reduce the incidence of epistaxis during nasotracheal intubation.

epistaxis associated with nasotracheal intubation can be from blood-tinged mucus to massive bleeding. epistaxis during nasotracheal intubation can cause excessive force during the procedure, use of an endotracheal tube (ett) larger than the nasal cavity, repeated intubation attempts, and abnormalities in the anatomy of the nose or nasopharynx. epistaxis during nasotracheal intubation can lead to several complications such as nasal discomfort, airway obstruction, and blood aspiration. topical vasoconstrictors such as oxymetazoline are used to reduce the incidence and severity of epistaxis caused by nasotracheal intubation. oxymetazoline nasal drops before nasotracheal intubation significantly increases the intranasal diameter and causes vasoconstriction of blood vessels, thereby reducing bleeding and damage to the nasal mucosa. epinephrine can be used as an alternative nasal decongestant to reduce the incidence of epistaxis during nasotracheal intubation. administering 1 ml of 0.1% topical epinephrine reduces 25% nasal mucosal volume and decreases 37% blood flow, thereby providing nasal cavity expansion with lower hemodynamic and systemic effects. currently, there exists a lack of empirical research regarding the utilization of epinephrine drops for the prophylaxis of epistaxis in the context of nasotracheal intubation. given this gap in the literature, the objective of this investigation is to conduct a comparative analysis between the application of 0.1% epinephrine nasal drops and 0.05% oxymetazoline nasal drops for the prevention of epistaxis during nasotracheal intubation procedures for oral surgery.

Eligibility criteria:
inclusion criteria: patients * underwent oral surgery with nasotracheal intubation * aged 18-50 years * asa (american society of anesthesiologists) physical status of 1-2. exclusion criteria: * allergy to the medications used * nasal congestion, nasal polyps, allergic rhinitis * hypertension and use of antihypertensive medications, * abnormal coagulation factors, receiving antithrombotic and anticoagulant therapy, * difficult intubation with a lemon score ≥4, * a history of nasal surgery or nasal trauma, * pregnancy, * heart abnormalities, * ischemic heart disease or arrhythmias, * symptoms of acute respiratory infection perioperatively, * liver and kidney function abnormalities, and * a history of spontaneous epistaxis